ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded up 95.8% on Thursday . The stock traded as high as GBX 2.49 ($0.03) and last traded at GBX 2.35 ($0.03). 42,281,480 shares were traded during trading, an increase of 431% from the average session volume of 7,956,301 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Up 4.9 %
The firm’s 50 day simple moving average is GBX 1.40 and its 200 day simple moving average is GBX 1.65. The company has a market capitalization of £15.30 million, a PE ratio of -367.30 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- Which Wall Street Analysts are the Most Accurate?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- 3 Best Fintech Stocks for a Portfolio Boost
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- How Technical Indicators Can Help You Find Oversold Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
